Quick Answer
Aurinia Pharmaceuticals Inc. reported Operating Income of $104.91 million for fiscal year 2025.
Aurinia Pharmaceuticals Inc. Operating Income — Annual History
| Fiscal Year | Operating Income | YoY Change |
|---|---|---|
| 2025 | $104.91M | +2338.4% |
| 2024 | -$4.69M | +94.9% |
| 2023 | -$91.69M | +17.7% |
| 2022 | -$111.47M | +38.3% |
| 2021 | -$180.74M | -73.3% |
| 2020 | -$104.29M | -14.7% |
| 2019 | -$90.94M | -64.6% |
| 2018 | -$55.24M | — |
Quarterly Operating Income
| Quarter Ending | Operating Income | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | $29.75M | +153.2% | +48.1% |
| June 30, 2025 | $20.08M | +1427.4% | -8.1% |
| March 31, 2025 | $21.85M | +264.8% | +86.0% |
| September 30, 2024 | $11.75M | +172.2% | +876.5% |
| June 30, 2024 | -$1.51M | +90.6% | +88.6% |
| March 31, 2024 | -$13.25M | +55.2% | +18.5% |
| September 30, 2023 | -$16.26M | -71.2% | -0.6% |
| June 30, 2023 | -$16.17M | +55.1% | +45.3% |
- Aurinia Pharmaceuticals Inc. showed an increase of +2338.4% in Operating Income compared to the prior fiscal year.
- Over the 2018–2025 period, Aurinia Pharmaceuticals Inc.’s operating income has grown by 289.9% (from -$55.24 million to $104.91 million).
- The most recent figure is from Aurinia Pharmaceuticals Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on February 26, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: